Bachem has a total of 47 patents globally, out of which 19 have been granted. Of these 47 patents, more than 58% patents are active. The USA is where Bachem has filed the maximum number of patents, followed by Europe (EPO) and Israel. Parallelly, Europe (EPO) seems to be the main focused R&D center of Bachem.
Bachem was founded in the year 1971. Company is a Swiss bio-technology company active in the fields of chemistry, biochemistry and pharmaceuticals.
Do read about some of the most popular patents of Bachem which have been covered by us in this article and also you can find Bachem patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Bachem patent portfolio.
How many patents does the CEO of Bachem have?
The CEO, Thomas Meier, has 0 patents.
How many patents does Bachem have?
Bachem has a total of 47 patents globally. These patents belong to 17 unique patent families. Out of 47 patents, 30 patents are active.
How Many Patents did Bachem File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
|Year of Patents Filing or Grant||Bachem Applications Filed||Bachem Patents Granted|
How many Bachem patents are Alive/Dead?
How Many Patents did Bachem File in Different Countries?
Where are Research Centers of Bachem Patents Located?
10 Best Bachem Patents
US8080523B2 is the most popular patent in the Bachem portfolio. It has received 21 citations so far.
Below is the list of 10 most cited patents of Bachem:
|Publication Number||Citation Count|
List of Bachem Patents
|US20220213139A1||Manufacture Of Disulfide Bonded Peptides|
|US11186608B2||Solid Phase Synthesis Of Acylated Peptides|
|US11117946B2||Method For Preparing Glucagon-Like Peptides|
|US20210122782A1||Manufacture Of Glucagon Peptides|
|US20200371069A1||Purification Of Glucagon-Like Peptide 1 Analogs|
|US10690635B2||Purification Of Glucagon-Like Peptide 1 Analogs|
|US20170274047A1||Analogs Of Shk Toxin And Their Uses In Selective Inhibition Of Kv1. 3 Potassium Channels|
|US9616102B2||Analogs Of Shk Toxin And Their Uses In Selective Inhibition Of Kv1.3 Potassium Channels|
|US9061071B2||Analogs Of Shk Toxin And Their Uses In Selective Inhibition Of Kv1.3 Potassium Channels|
|US8569452B2||Preparation Of Phalloidin And Its Derivatives|
|US8440621B2||Analogs Of Shk Toxin And Their Uses In Selective Inhibition Of Kv1.3 Potassium Channels|
|US8080523B2||Analogs Of Shk Toxin And Their Uses In Selective Inhibition Of Kv1.3 Potassium Channels|
|EP4161942A1||Improved Oligonucleotide Synthesis|
|EP3433267B1||Method For Preparing Glucagon-Like Peptides|
|EP3956343A1||Manufacture Of Disulfide Bonded Peptides|
|EP3433268B1||Purification Of Glucagon-Like Peptide 1 Analogs|
|EP3728304A1||Solid Phase Synthesis Of Acylated Peptides|
|EP2474316B1||Analogs Of Shk Toxin And Their Uses In Selective Inhibition Of Kv1.3 Potassium Channels|
|EP1724260B1||Process For The Synthesis Of (2S, 3Ar, 7As)Octahydroindole-2-Carboxylic Acid And Its Conversion To Trandolapril|
|EP1864973A1||Process For The Preparation Of Perindopril And Salts Thereof|
|EP1466884A1||Process For The Preparation Of Resveratrol And Its Uses|
|CN109641946A||Method For Preparing Glucagon-Like Peptides|
|CN109311960A||Purification Of Glucagon-Like Peptide 1 Analogs|
|WO2022214692A1||Pseudo Solid Phase Protecting Group And Methods For The Synthesis Of Oligonucleotides And Oligonucleotide Conjugates|
|WO2022195111A1||Improved Oligonucleotide Synthesis|
|WO2020212477A1||Manufacture Of Disulfide Bonded Peptides|
|WO2019149723A1||Manufacture Of Glucagon Peptides|
|WO2019120639A1||Solid Phase Synthesis Of Acylated Peptides|
|WO2017162650A1||Method For Preparing Glucagon-Like Peptides|
|WO2017162653A1||Purification Of Glucagon-Like Peptide 1 Analogs|
|CA3018618A1||Method For Preparing Glucagon-Like Peptides|
|CA3018627A1||Purification Of Glucagon-Like Peptide 1 Analogs|
|CA2582149C||Analogs Of Shk Toxin And Their Uses In Selective Inhibition Of Kv1.3 Potassium Channels|
|DE602017060962T2||Process For Production Of Glucagon-Like Peptides|
|IL287199A||Manufacture Of Disulfide Bonded Peptides|
|DE602017042857T2||Purification Of Glucagon-Like Peptide-1 Analogues|
|IL276067A||Manufacture Of Glucagon Peptides|
|IL261846A||Purification Of Glucagon-Like Peptide 1 Analogs|
|IL261845A||Method For Preparing Glucagon-Like Peptides|
|HK1173079A1||Analogs Of Shk Toxin And Their Uses In Selective Inhibition Of Kv1.3 Potassium Channels|
|ES2580233T3||Analogs Of Shk Toxin And Their Uses In Selective Inhibition Of Kv1.3 Potassium Channels|
|DE602005048922T2||Analogs Of Shk Toxin And Their Use In The Selective Inhibition Of Kv1.3 Potassium Channels|
|DE602005004897D1||Process For The Preparation Of I(2S,3Ar,7As)-Octahydroindole-2-Carboxylic Acid And Conversion To Trandolapril|
|AT386718T||Process For Production Of (2S, 3Ar, 7As)- Octahydroindole-2-Carbonic Acid And Conversion To Trandolapril|
|GB0504857D0||Novel Compounds And Their Effects On Feeding Behaviour|
What are Bachem’s key innovation segments?
What Technologies are Covered by Bachem?
The chart below distributes patents filed by Bachem